Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 205

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Ibrutinib-Associated Atrial Fibrillation

Open access
Ganatra, Sarju, Sharma, Ajay, Shah, Sachin, Chaudhry, Ghulam M., Martin, David T., Neilan, Tomas G., Mahmood, Syed Saad, Barac, Ana, Groarke, John D., Hayek, Salim S., Dani, Saurbha, Venesy, David, Patten, Richard, Nohria, Anju · 2018 · JACC: Clinical Electrophysiology

Abstract

Ibrutinib, a novel and potent Bruton tyrosine kinase inhibitor, is an effective and well-tolerated treatment for a variety of B-cell lymphomas. However, its use is associated with an increased incidence of atrial fibrillation (AF), ranging from 4% to 16%. We reviewed the original clinical trials that led to the approval of ibrutinib, as well as several other prospective and retrospective studies, to better appreciate the incidence of ibrutinib-associated AF. Based on 16 studies included in our analysis, the incidence of ibrutinib-associated AF was 5.77 per 100 person-years, which is much higher than rates previously reported with ibrutinib and compared with the general adult population. New onset AF in cancer patients is associated with a significantly higher risk of heart failure and thromboembolism, even after adjusting for known risk factors. In addition, ibrutinib poses unique challenges due to its interactions with many medications that are commonly used to manage AF. Ibrutinib also inhibits platelet activation and decisions regarding anticoagulation have to be carefully weighed against this increased risk of bleeding. Ibrutinib's interaction with calcium channel blockers, digoxin, amiodarone, and direct oral anticoagulants can result in either ibrutinib or other drug-related toxicity and careful selection and dose adjustment may be needed. Ibrutinib-associated AF can be a therapy-limiting side effect and physicians should be familiar with the special management considerations imposed by this agent. We review the potential mechanisms and incidence of ibrutinib-associated AF and propose an algorithm for its management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacep.2018.06.004

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 205

Metadata

Authors
Ganatra, S., Sharma, A., Shah, S., Chaudhry, G. M., Martin, D. T., Neilan, T. G., Mahmood, S. S., Barac, A., Groarke, J. D., Hayek, S. S., Dani, S., Venesy, D., Patten, R., & Nohria, A.
Venue
JACC: Clinical Electrophysiology
Publisher
Elsevier BV
Published
2018-12
Volume
4
Issue
12
Pages
1491-1500
ISSN
2405-500X (ISSN-L)
OpenAlex
W2889134442
Cited by
205
References
5
FWCI
13.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ibrutinib-Associated Atrial Fibrillation. https://app.cochat.ai/papers/10.1016/j.jacep.2018.06.004
The paper
Ganatra, S., Sharma, A., Shah, S., Chaudhry, G. M., Martin, D. T., Neilan, T. G., Mahmood, S. S., Barac, A., Groarke, J. D., Hayek, S. S., Dani, S., Venesy, D., Patten, R., & Nohria, A. (2018). Ibrutinib-Associated Atrial Fibrillation. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2018.06.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.